Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference newsletter


  Ovarian Neoplasms

  Free Subscription


Articles published in Cancer Chemother Pharmacol

Retrieve available abstracts of 32 articles:
HTML format



Single Articles


    October 2020
  1. HANSEN MKG, Smerdel MP, Waldstrom M, Andersen RF, et al
    Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients.
    Cancer Chemother Pharmacol. 2020 Oct 16. pii: 10.1007/s00280-020-04162.
    PubMed     Abstract available


    August 2020
  2. JIANG J, Wang S, Wang Z, Cai J, et al
    HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer.
    Cancer Chemother Pharmacol. 2020 Aug 2. pii: 10.1007/s00280-020-04120.
    PubMed     Abstract available


    June 2020
  3. ZHU Y, Liu Z, Qu Y, Zeng J, et al
    YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects.
    Cancer Chemother Pharmacol. 2020 Jun 9. pii: 10.1007/s00280-020-04098.
    PubMed     Abstract available


    April 2020
  4. SOYAMA H, Miyamoto M, Matsuura H, Iwahashi H, et al
    Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine.
    Cancer Chemother Pharmacol. 2020 Apr 11. pii: 10.1007/s00280-020-04070.
    PubMed     Abstract available


    January 2020
  5. WANG Z, Gao J, Ohno Y, Liu H, et al
    Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib.
    Cancer Chemother Pharmacol. 2020 Jan 6. pii: 10.1007/s00280-019-04025.
    PubMed     Abstract available


    November 2019
  6. KASHANI B, Zandi Z, Bashash D, Zaghal A, et al
    Small molecule inhibitor of TLR4 inhibits ovarian cancer cell proliferation: new insight into the anticancer effect of TAK-242 (Resatorvid).
    Cancer Chemother Pharmacol. 2019 Nov 30. pii: 10.1007/s00280-019-03988.
    PubMed     Abstract available


  7. KUBECEK O, Martinkova J, Chladek J, Blaha M, et al
    Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer.
    Cancer Chemother Pharmacol. 2019 Nov 14. pii: 10.1007/s00280-019-03976.
    PubMed     Abstract available


    October 2019
  8. ZHENG Y, Zhu J, Zhang H, Liu Y, et al
    Metformin plus first-line chemotherapy versus chemotherapy alone in the treatment of epithelial ovarian cancer: a prospective open-label pilot trial.
    Cancer Chemother Pharmacol. 2019 Oct 18. pii: 10.1007/s00280-019-03963.
    PubMed     Abstract available


    August 2019
  9. MIRZA MR, Bergmann TK, Mau-Sorensen M, Christensen RD, et al
    A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
    Cancer Chemother Pharmacol. 2019 Aug 2. pii: 10.1007/s00280-019-03917.
    PubMed     Abstract available


    April 2019
  10. KOBAYASHI-KATO M, Yunokawa M, Bun S, Miyasaka N, et al
    Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer.
    Cancer Chemother Pharmacol. 2019 Apr 13. pii: 10.1007/s00280-019-03834.
    PubMed     Abstract available


  11. MOORE K, Chan JK, Secord AA, Patel MR, et al
    Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Cancer Chemother Pharmacol. 2019;83:717-726.
    PubMed     Abstract available


    January 2019
  12. STARLING BR, Kumar P, Lucas AT, Barrow D, et al
    Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients.
    Cancer Chemother Pharmacol. 2019;83:61-70.
    PubMed     Abstract available


    October 2018
  13. LINDEMANN K, Beale PJ, Rossi E, Goh JC, et al
    Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103).
    Cancer Chemother Pharmacol. 2018 Oct 27. pii: 10.1007/s00280-018-3706.
    PubMed     Abstract available


    September 2018
  14. BANERJI U, Sain N, Sharp SY, Valenti M, et al
    Correction to: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.
    Cancer Chemother Pharmacol. 2018 Sep 1. pii: 10.1007/s00280-018-3674.
    PubMed     Abstract available


    July 2018
  15. BHOWMIK S, Bhowmick S, Maiti K, Chakra A, et al
    Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil((R)) or Caelyx((R)) in advanced ovarian cancer.
    Cancer Chemother Pharmacol. 2018 Jul 11. pii: 10.1007/s00280-018-3643.
    PubMed     Abstract available


    April 2018
  16. LEE J, Curtin JP, Muggia FM, Pothuri B, et al
    Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer.
    Cancer Chemother Pharmacol. 2018 Apr 27. pii: 10.1007/s00280-018-3591.
    PubMed     Abstract available


    March 2018
  17. XIAO F, Li Y, Wan Y, Xue M, et al
    MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
    Cancer Chemother Pharmacol. 2018 Mar 28. pii: 10.1007/s00280-018-3548.
    PubMed     Abstract available


  18. TAKASAKI K, Miyamoto M, Takano M, Soyama H, et al
    Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis.
    Cancer Chemother Pharmacol. 2018 Mar 2. pii: 10.1007/s00280-018-3552.
    PubMed     Abstract available


    February 2018
  19. MORGAN RD, Clamp AR, Evans DGR, Edmondson RJ, et al
    PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
    Cancer Chemother Pharmacol. 2018 Feb 20. pii: 10.1007/s00280-018-3532.
    PubMed     Abstract available


  20. ISHIKAWA M, Kawai M, Maeda T, Kagawa Y, et al
    Prediction of neutrophil reduction using plasma paclitaxel concentration after administration in patients with uterine, ovarian, or cervical cancers in an outpatient clinic.
    Cancer Chemother Pharmacol. 2018;81:399-411.
    PubMed     Abstract available


    January 2018
  21. MOORE K, Zhang ZY, Agarwal S, Burris H, et al
    The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer.
    Cancer Chemother Pharmacol. 2018 Jan 10. pii: 10.1007/s00280-017-3512.
    PubMed     Abstract available


  22. VAN ANDEL L, Rosing H, Zhang Z, Hughes L, et al
    Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients.
    Cancer Chemother Pharmacol. 2018;81:39-46.
    PubMed     Abstract available


    December 2017
  23. CORTEZ AJ, Tudrej P, Kujawa KA, Lisowska KM, et al
    Advances in ovarian cancer therapy.
    Cancer Chemother Pharmacol. 2017 Dec 16. pii: 10.1007/s00280-017-3501.
    PubMed     Abstract available


  24. YOSHINO K, Kamiura S, Yokoi T, Nakae R, et al
    Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6).
    Cancer Chemother Pharmacol. 2017;80:1239-1247.
    PubMed     Abstract available


    November 2017
  25. LIU X, Jiang Y, Nowak B, Qiang B, et al
    Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.
    Cancer Chemother Pharmacol. 2017 Nov 30. pii: 10.1007/s00280-017-3483.
    PubMed     Abstract available


    October 2017
  26. FIEDOR E, Gregoraszczuk EL
    Superactive human leptin antagonist (SHLA), triple Lan1 and quadruple Lan2 leptin mutein as a promising treatment for human folliculoma.
    Cancer Chemother Pharmacol. 2017;80:815-827.
    PubMed     Abstract available


    September 2017
  27. YOSHIKAWA T, Takano M, Miyamoto M, Yajima I, et al
    Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers.
    Cancer Chemother Pharmacol. 2017;80:555-561.
    PubMed     Abstract available


    August 2017
  28. MENDIVIL AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, et al
    Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience.
    Cancer Chemother Pharmacol. 2017;80:405-410.
    PubMed     Abstract available


    June 2017
  29. SHOJI T, Takatori E, Omi H, Kagabu M, et al
    A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).
    Cancer Chemother Pharmacol. 2017 Jun 27. doi: 10.1007/s00280-017-3363.
    PubMed     Abstract available


    May 2017
  30. WANG YY, Chen YK, Hu SC, Hsu YL, et al
    CYT-Rx20 inhibits ovarian cancer cells in vitro and in vivo through oxidative stress-induced DNA damage and cell apoptosis.
    Cancer Chemother Pharmacol. 2017 May 12. doi: 10.1007/s00280-017-3330.
    PubMed     Abstract available


    March 2017
  31. MITTAPALLI RK, Nuthalapati S, Shepherd SP, Xiong H, et al
    Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
    Cancer Chemother Pharmacol. 2017;79:587-594.
    PubMed     Abstract available


    February 2017
  32. ZHANG J, Liu J, Xu X, Li L, et al
    Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer.
    Cancer Chemother Pharmacol. 2017 Feb 8. doi: 10.1007/s00280-017-3238.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: